This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at email@example.com or call 800-767-3771 ext. 9339.
For Immediate Release
Chicago, IL – December 21, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Novo Nordisk (NVO - Analyst Report), Sanofi (SNY - Analyst Report), Eli Lilly and Company (LLY - Analyst Report), Merck & Co. Inc. (MRK - Analyst Report) and Johnson & Johnson (JNJ - Analyst Report).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Thursday’s Analyst Blog:
Novo Progresses with Pipeline
Novo Nordisk (NVO - Analyst Report) recently completed a phase IIIa study on IDegLira, which is a combination of Tresiba (insulin degludec) and Victoza (liraglutide). Novo Nordisk is evaluating IDegLira for the treatment of patients suffering from type II diabetes.
The phase III study (DUAL II) enrolled around 400 patients suffering from type II diabetes and previously insufficiently controlled on basal insulin in combination with 1–2 oral anti-diabetic agents. The study results showed that patients treated with IDegLira or Tresiba plus metformin achieved superiority compared to standalone therapy with Tresiba.
The study revealed that around 60% of the patients who used IDegLira achieved the HbA1c target of 7% (recommended by the American Diabetes Association and the European Association for the Study of Diabetes). Moreover, 45% of the patients reached the HbA1c target of 6.5% (recommended by the American Academy of Clinical Endocrinology).
Both IDegLira and Tresiba have been reported safe and tolerable. Novo Nordisk did not report any disparity between the two treatment arms as to adverse reactions and normal safety parameters.
We note that Novo Nordisk had announced results from the first phase IIIa trial of IDegLira, DUAL I, in August this year, which demonstrated an impressive efficacy profile. Novo Nordisk now plans to file regulatory applications in both the US and the EU in 2013.
Although Novo Nordisk holds a strong position in the diabetes market, we note that the diabetes market is highly crowded with players like Sanofi (SNY - Analyst Report), Eli Lilly and Company (LLY - Analyst Report) and Merck & Co. Inc. (MRK - Analyst Report).
We have an Outperform recommendation on Denmark-based Novo Nordisk. The stock carries a Zacks #2 Rank (Buy). Other large cap pharma company, that carry a Zacks #2 Rank is Johnson & Johnson (JNJ - Analyst Report).
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339